$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Zolbetuximab-Vyloy was developed by which company
2026-02-01 22:25:32
Check Details
Zolbetuximab-Vyloy Buying Guide: How to Get This New Gastric Cancer Targeting Drug
2026-02-01 22:25:32
Check Details
The difference between midostaurin and giritinib: analysis of mechanism of action, indications and efficacy
2026-02-01 22:25:32
Check Details
Zolbetuximab - Difference Between Vyloy and Rituximab
2026-02-01 22:25:32
Check Details
2025Zolbetuximab (Zolbetuximab)-Vyloy How much does it cost to buy it?
2026-02-01 22:25:32
Check Details
What is the dosage, dosage and best time to take Avonib?
2026-02-01 22:25:32
Check Details
What is the mechanism of action of mitotane? Is it a targeted drug or a chemotherapy drug?
2026-02-01 22:25:32
Check Details
What are the metabolic pathways of erlotinib? What cancers does it work for?
2026-02-01 22:25:32
Check Details
How effective is tofacitinib in rheumatoid arthritis? How long does it take to take effect?
2026-02-01 22:25:32
Check Details
What diseases is cycloserine used to treat? What are its side effects?
2026-02-01 22:25:32
Check Details
Which is more effective, linezolid or vancomycin? How to choose clinically?
2026-02-01 22:25:32
Check Details
Is Ribociclib included in Medicare? How much does the patient need to pay out of pocket after reimbursement?
2026-02-01 22:25:32
Check Details
1
2
...
1322
1323
1324
1325
1326
1327
1328
...
10224
10225
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Dosing Duration, Efficacy Comparison, and Long-Term Management
2
Belzutifan (Welireg): Comprehensive Guide to the First HIF-2α Inhibitor — Indications, Dosing, and Safety Monitoring
3
Encorafenib (Braftovi): Comprehensive Guide to BRAF V600 Inhibitor Indications, Dose Regimens by Tumor Type, and Administration Requirements
4
Tazemetostat: Mechanism, Standard Dosing, and the 2026 Global Withdrawal of the First-in-Class EZH2 Inhibitor
5
FDA Approves Orzeyful, the World's First Orexin Receptor Agonist for Narcolepsy Type 1, Ushering in a New Era of Root-Cause Therapy
6
Alpelisib vs Inavolisib: How to Choose Between Two PI3Kα Inhibitors in PIK3CA-Mutated Breast Cancer
7
Selumetinib: The First MEK1/2 Inhibitor Approved for Inoperable Plexiform Neurofibromas in NF1
8
FIGHT-302 Phase 3 Trial: First-Line Pemigatinib Significantly Improves PFS Over Chemotherapy in FGFR2-Rearranged Cholangiocarcinoma
9
Selpercatinib Dosing Guide: Weight-Based Precision Targeting for RET-Driven Tumors
10
Mitotane Side Effects: Understanding Key Risks in Adrenocortical Carcinoma Therapy
11
Ponatinib: A Third-Generation TKI Targeting BCR::ABL1 to Overcome Leukemia Drug Resistance
12
Axitinib: Indications, Mechanism of Action & Key Safety Warnings